文献速递甲状腺疾病

转移性甲状腺髓样癌:68镓-DOTA-生长抑素类似物PET/CT与肽受体放射性核素治疗的作用

Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

远处转移患者中仅26%有≥50%病灶摄取值高于肝背景,16%有>90%摄取;21例接受PRRT者中位至治疗失败时间14个月,中位总生存63个月。结论认为高摄取患病率低,但PRRT对部分选定患者仍可行。

要点

  • 转移性MTC中68Ga-DOTA-SSA PET/CT高摄取患病率低,仅少数患者适合PRRT。
  • PRRT组中位至治疗失败14个月,中位总生存63个月。
  • 降钙素倍增时间≤24个月、18F-FDG高摄取和年龄≥60岁提示总生存更差。

核心结论

  • 转移性MTC中68Ga-DOTA-SSA PET/CT高肿瘤摄取患病率低,但PRRT对部分选定患者仍可能是可行治疗选择。

主要发现

  • 远处转移患者中16例(26%)有≥50%病灶摄取值高于肝背景,10例(16%)有>90%摄取。
  • 19例有同期增强CT者中,68Ga-DOTA-SSA PET/CT未独立识别出任何病变区域。
  • 21例接受PRRT,中位至治疗失败时间14个月(95%CI 8-25),中位总生存63个月(95%CI 21-未达到)。
  • 全队列中位总生存323个月(95%CI 152-未达到);总生存更差的预测因素包括降钙素倍增时间≤24个月、18F-FDG强摄取和年龄≥60岁。

临床怎么用

  • 对转移性MTC可考虑68Ga-DOTA-SSA PET/CT评估生长抑素受体表达,以筛选PRRT候选者。
  • 18F-FDG PET/CT可补充识别68Ga-DOTA-SSA阴性病灶,两者联合有助于全面评估。

局限性

  • 回顾性设计,PRRT疗效仅在亚组中探索,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metastatic medullary thyroid cancer (MTC) is a rare malignancy with minimal treatment options. Many, but not all, MTCs express somatostatin receptors. OBJECTIVE: Our aim was to explore the role of 68Ga-DOTA-somatostatin analogue (SSA) positron emission tomography (PET)/computed tomography (CT) in patients with metastatic MTC and to determine their eligibility for peptide receptor radionuclide therapy (PRRT). METHODS: We retrospectively identified patients with metastatic MTC who had 68Ga-DOTA-SSA PET/CT at 5 centers. We collected characteristics on contrast-enhanced CT, 68Ga-DOTA-SSA and 18F-FDG PET/CT. The efficacy of PRRT was explored in a subgroup of patients. Kaplan-Meier analysis was used to estimate time to treatment failure (TTF) and overall survival (OS). RESULTS: Seventy-one patients were included (10 local recurrence, 61 distant disease). Of the patients with distant disease, 16 (26%) had ≥50% of disease sites with tracer avidity greater than background liver, including 10 (10/61, 16%) with >90%. In 19 patients with contemporaneous contrast-enhanced CT, no disease regions were independently identified on 68Ga-DOTA-SSA PET/CT. Thirty-five patients had an 18F-FDG PET/CT, with 18F-FDG positive/68Ga-DOTA-SSA negative metastases identified in 15 (43%). Twenty-one patients had PRRT with a median TTF of 14 months (95% CI 8-25) and a median OS of 63 months (95% CI 21-not reached). Of the entire cohort, the median OS was 323 months (95% CI 152-not reached). Predictors of poorer OS included a short calcitonin doubling-time (≤24 months), strong 18F-FDG avidity, and age ≥60 years. CONCLUSIONS: The prevalence of high tumor avidity on 68Ga-DOTA-SSA PET/CT is low in the setting of metastatic MTC; nevertheless, PRRT may still be a viable treatment option in select patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hayes AR, Crawford A, Al Riyami K, et al. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2021. PMID: 34379772. doi:10.1210/clinem/dgab588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。